- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Strategies for Equitable Access in Hidradenitis Suppurativa
Panelist discusses how rapid access clinics could revolutionize HS patient care by providing swift, comprehensive diagnostic pathways, integrating multidisciplinary expertise, and enabling early intervention. Strategies for equitable access include telemedicine, mobile diagnostic units, community health worker training, sliding-scale pricing, and partnerships with local health care providers to overcome geographical and economic barriers in underserved regions.
EP: 1.Bridging the Gap in Recognizing Early Symptoms of Hidradenitis Suppurativa
EP: 2.Improving HS Diagnosis and Care Through Better Alignment of Staging and Severity
EP: 3.Addressing Social Determinants of Health in Hidradenitis Suppurativa Care
EP: 4.Economic Implications of Diagnostic Delays in Hidradenitis Suppurativa
EP: 5.Strategies for Equitable Access in Hidradenitis Suppurativa
EP: 6.Partnering With Patient Advocacy Groups to Improve HS Awareness and Outcomes
EP: 7.Holistic Care for HS Patients: The Power of Multidisciplinary Models
EP: 8.The Case for HS Centers of Excellence: Evidence for Improved Patient Outcomes
EP: 9.Innovating HS Care: Applying Multidisciplinary Lessons to Diagnosis and Management
EP: 10.The Value Proposition: Justifying the Investment in HS Centers of Excellence
EP: 11.Key Takeaways on HS Care: Multidisciplinary Collaboration and Equity Solutions
EP: 12.Navigating HS Management: The Patient Journey
Video content above is prompted by the following:
- In what ways could rapid access clinics serve as a model for early diagnosis and coordinated care for HS patients?
- What strategies can be employed to ensure equitable access to diagnostic services for patients in underserved areas?
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
Solving the Transition Conundrum as More Children With Muscular Dystrophy Live to Adulthood
March 17th 2025Learning from examples like congenital heart disease and cystic fibrosis can help health systems and clinicians prepare to care for an influx of patients with neuromuscular diseases as they reach adulthood thanks to transformative therapy advances.
Read More
